Protocol SummaryBack To Search Instructions
Protocol No.ML28897PRO/02Principal InvestigatorGrilley-Olson, Juneko
PhasePhase II
Oncology GroupPhase 1
Management GroupClinical Protocol Office; Phase 1 CPO
Age GroupAdultScopeNational
Secondary Protocol No.ML28897/PRO 02
TitleMy Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.
Applicable Disease SitesBones and Joints
Brain and Nervous System
Breast
Breast - Male
Cervix Uteri
Colon
Corpus Uteri
Esophagus
Eye and Orbit
Kidney
Larynx
Lip, Oral Cavity and Pharynx
Liver
Lung
Melanoma, Skin
Ovary
Pancreas
Prostate
Rectum
Small Intestine
Soft Tissue
Stomach
Thyroid
Urinary Bladder
Drugs InvolvedAtezolizumab
HERCEPTIN (TRASTUZUMAB)
PERTUZUMAB
TRASTUZUMAB
alectinib
StatusOpen
Participating InstitutionsUNC-CH
Eligibility DocumentPRO 02 Pre-screening Form_v 17_15March2019.pdf
ClinicialTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02091141
Back to Protocol Listing